I. MODIFIED AGREEMENTS | ||||
Biotech Co.* | Pharma Co. | Change | Disclosed | Terms/Details |
(Symbol) | (Country) | from original | Funding | (Date) |
agreement | ($M) | |||
Actelion Ltd. | R.W. Johnson | Extended for a third year a collaboration to discover compounds targeting the vascular endothelium | ND | Actelion will continue to combine its base in vascular endothelium biology with expertise in medical chemistry to discover the compounds; Johnson & Johnson will develop and commercialize any new drugs arising from the project (6/25) |
Alliance | Baxter | Modified agreement for Oxygent development | $30 | Baxter will make a $4M investment in Series F preferred stock, as well as an additional $3M investment later in May; Baxter must make an additional investment of $23M by the end of September (5/2) |
ComGenex | Bayer AG | Extension of the companies' combinatorial supply agreement | ND | The extension will strive to increase the number of potentially bioactive compound libraries co-designed and delivered to Bayer (5/15) |
GenVec | Varian | Extension to a collaboration made in 1998 for treatments of cancer | ND | Extension will last through 2004; collaborative agreement will combine advances in gene therapy products with targeted radiation therapy (6/20) |
Neose | Bristol-Myers | Research and development agreement reassigned to Progenics Pharmaceuticals Inc. | ND | The change is in connection with Progenics' reacquisition of development and marketing rights from BMS of two cancer vaccine programs; Progenics has the right to negotiate with Neose for the supply of the two gangliosides for use as the active pharmaceutical ingredients in the cancer vaccines (5/18) |
Paradigm | Bayer AG | Extended and expanded research agreement to develop herbicides | $30 | The five-year deal, worth up to $30M, is an extension to a $40M deal signed in 1998 (6/19) |
Progenics Pharmaceuticals | F. Hoffmann- | Renewal of a research collaboration focused on the discovery and development of novel therapeutics | ND | The program aims to identify drugs that target HIV coreceptors (4/27) |
Trimeris Inc. | Hoffmann- | Expanded agreement to discover and develop peptides | ND | Companies will develop novel generations of HIV fusion inhibitor peptides (6/19) |
Zycos Inc.* | Aventis | Extended drug discovery collaboration on an undisclosed cancer antigen | ND | Collaboration was originally initiated in 1999; extended agreement provides Zycos with additional research and development payments, milestone payments and royalties on any commercialized products (6/25) |
II. TERMINATED AGREEMENTS | ||||
BioCryst | Ortho-McNeil | Terminated worldwide license agreement for the flu treatment, RWJ-270201 | ND | Termination returns to BioCryst rights to the influenza neuraminidase inhibitors; Ortho-McNeil will maintain any work in progress for the next four months (4/30) |
Digene Corp. | Abbott | Terminated marketing and distribution agreement for Digene's human papillomavirus DNA tests and accessories | ND | Abbott and Digene terminated their agreement (5/2) |
Genentech Inc. | Schwarz | Terminated agreement of rights to two growth hormone products, Nutropin AQ and Nutropin Depot | ND | Genentech reaacquired rights to the products in Europe and certain other countries outside Canada, the U.S., China and Japan (6/8) |
Peregrine | Schering AG | Terminated development agreement for Oncolym | ND | Peregrine negotiated with Schering to take back development of Oncolym, which was licensed to Schering in March 1999 (6/8) |
Pharmacyclics | Nycomed | Terminated rights agreement for Lutrin | $2.75 | Termination returns worldwide rights to Pharmacyclics; the company now has worldwide rights in Eruope, Asia, and South and Central America; Amersham will pay a one-time $2.75M fee to cover future research and development obligations (5/4) |
Progenics | Bristol- | Terminated collaboration for GMK and MGV cancer vaccines | $15.5 | The companies are terminating their agreement to develop the vaccines; Progenics will receive $15.5M and regain all rights to the products (5/15) |
NOTES | ||||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | ||||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
ND = Not disclosed, reported and/or available | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; TSE = Toronto Stock Exchang; VSE = Vancouver Stock Exchange. | ||||
